Utilize este identificador para referenciar este registo: https://hdl.handle.net/10316/106496
Título: Salvia ceratophylla L. from South of Jordan: new insights on chemical composition and biological activities
Autor: Abu-Darwish, Mohammad Sanad
Cabral, Célia 
Ali, Zulfigar
Wang, Mei
Khan, Shabana I.
Jacob, Melissa R.
Jain, Surendra K.
Tekwani, Babu L.
Zulfiqar, Fazila
Khan, Ikhlas A.
Taifour, Hatem
Salgueiro, Lígia 
Efferth, Thomas
Palavras-chave: Lamiaceae; Essential oil; Chemical composition; Cytotoxicity; Anti-inflammatory activity; Neglected diseases
Data: Out-2020
Editora: Springer Nature
Título da revista, periódico, livro ou evento: Natural Products and Bioprospecting
Volume: 10
Número: 5
Resumo: In Jordan, Salvia ceratophylla L. is traditionally used in the treatment of cancer, microbial infections, and urinary disorders. This study aimed: (1) to chemically characterize S. ceratophylla essential oil (EO) from South Jordan, by gas chromatography (GC) and gas chromatography-mass spectrometry (GC-MS); and (2) to evaluate in vitro the cytotoxic, anti-inflammatory, and antiprotozoal activities of the EO, it's predominant components, and the hexane (A), ethyl acetate (B), methanol (C) and crude-methanol extracts (D). The analysis revealed that the EO has 71 compounds, with linalool (54.8%) as main constituent. Only the hexane extract (A) showed some cytotoxic activity against SK-MEL, KB, BT-549, SK-OV-3, LLC-PK1 and VERO cells lines with IC50 between 60 and > 100 µg/mL. The EO inhibited NO production (IC50 90 µg/mL) and NF-κB activity (IC50 38 µg/mL). The extracts A, B, and D inhibited NO production and NF- κB activity with IC50 between 32 and 150 µg/mL. Linalool considerably inhibited NO production (IC50 18 µg/mL). The extracts tested did not exhibit antileishmanial activity. Regarding antitrypanosomal activity, the EO exhibited significant results with IC50 2.65 µg/mL. In conclusion, Jordan S. ceratophylla EO represents a rich source of linalool and bears a promising therapeutic potential for further antitrypanosomal drug development.
URI: https://hdl.handle.net/10316/106496
ISSN: 2192-2195
DOI: 10.1007/s13659-020-00259-9
Direitos: openAccess
Aparece nas coleções:I&D ICBR - Artigos em Revistas Internacionais

Mostrar registo em formato completo

Citações SCOPUSTM   

7
Visto em 28/out/2024

Citações WEB OF SCIENCETM

7
Visto em 2/out/2024

Visualizações de página

95
Visto em 30/out/2024

Downloads

28
Visto em 30/out/2024

Google ScholarTM

Verificar

Altmetric

Altmetric


Este registo está protegido por Licença Creative Commons Creative Commons